Marvel Biosciences Corp (TSE:MRVL) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Marvel Biosciences Corp. has partnered with the FRAXA Research Foundation to test its lead compound, MB204, in a preclinical model for Fragile X syndrome, a condition linked to autism and intellectual disabilities. With no current approved treatment for FXS, the novel MB204, a derivative of an anti-Parkinson’s drug, shows promise in addressing this genetic disorder as well as possibly benefiting autism spectrum disorder and other neurological conditions.
For further insights into TSE:MRVL stock, check out TipRanks’ Stock Analysis page.